Want to see HK:9939 full AI Analyst Report?
Top Page
Kintor Pharmaceutical Ltd
(9939)
Select Model
Select Model
Rating:42Neutral
Price Target:
HK$1.50
▼(-11.24% Downside)
Action:Reiterated
Date:06/27/26
The score is held down primarily by weak financial quality (ongoing losses, negative gross profit, and continued cash burn with shrinking equity) and bearish technicals (price below all key moving averages with negative MACD). Valuation provides limited support due to negative earnings and no indicated dividend yield.
Positive Factors
Revenue Rebound
The sharp 2025 revenue rebound indicates improved commercial activity or pipeline monetization. Sustaining this recovery could strengthen operating leverage and provide a larger base for future licensing or product-related income.
Negative Factors
Persistent Unprofitability
Negative gross margins and recurring operating losses show that the business has not established sustainable economics. Without a durable improvement in product or partnership income, continued R&D spending will remain difficult to support.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Rebound
The sharp 2025 revenue rebound indicates improved commercial activity or pipeline monetization. Sustaining this recovery could strengthen operating leverage and provide a larger base for future licensing or product-related income.
Read all positive factors
Kintor Pharmaceutical Ltd (9939) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$894.43M
Dividend YieldN/A
Average Volume (3M)1.15M
Price to Earnings (P/E)―
Beta (1Y)1.51
Revenue Growth647.17%
EPS Growth-8.86%
CountryHK
Employees122
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.41
Shares Outstanding498,660,100
10 Day Avg. Volume1,820,350
30 Day Avg. Volume1,150,650
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)4.33
Price to Sales (P/S)24.23
P/FCF Ratio-4.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kintor Pharmaceutical Ltd Business Overview & Revenue Model
Company Description
Kintor Pharmaceutical Limited, a biotechnology firm in its clinical development phase, is dedicated to the discovery, advancement, and marketing of a diverse array of small molecule and biological therapies. The company primarily concentrates on a...
How the Company Makes Money
Kintor Pharmaceutical Ltd’s business model is typical of a clinical-stage biopharmaceutical developer: it invests in R&D to advance proprietary drug candidates and seeks to monetize them primarily through (i) out-licensing and collaboration arrang...
Kintor Pharmaceutical Ltd Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 77.57M | 32.68M | 5.00M | 0.00 | 0.00 | 34.23M |
| Gross Profit | 9.75M | 8.04M | -4.73M | -67.63M | -21.38M | 34.23M |
| EBITDA | -159.18M | -140.66M | -128.37M | -1.06B | -956.45M | -829.09M |
| Net Income | -189.63M | -200.11M | -155.29M | -1.06B | -954.37M | -842.10M |
Balance Sheet | ||||||
| Total Assets | 318.88M | 340.95M | 515.13M | 869.23M | 2.06B | 2.07B |
| Cash, Cash Equivalents and Short-Term Investments | 31.79M | 34.78M | 148.69M | 455.50M | 875.08M | 1.06B |
| Total Debt | 133.56M | 86.64M | 133.01M | 253.92M | 286.39M | 159.73M |
| Total Liabilities | 209.68M | 158.28M | 221.05M | 411.12M | 559.95M | 412.83M |
| Stockholders Equity | 109.20M | 182.67M | 294.08M | 458.11M | 1.50B | 1.66B |
Cash Flow | ||||||
| Free Cash Flow | -99.68M | -166.07M | -200.76M | -390.30M | -988.73K | -1.13M |
| Operating Cash Flow | -149.83M | -165.34M | -199.08M | -387.58M | -961.26K | -1.05M |
| Investing Cash Flow | 267.76K | 14.04M | 20.03M | 3.27M | 67.19K | 92.00K |
| Financing Cash Flow | 126.54M | 39.23M | -119.67M | -33.46M | 815.75K | 857.42K |
Kintor Pharmaceutical Ltd Technical Analysis
Positive
1.69
Price Trends
1.79
Positive
2.21
Negative
2.37
Negative
Market Momentum
>-0.01
Negative
52.48
Neutral
62.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9939, the sentiment is Positive. The current price of 1.69 is below the 20-day moving average (MA) of 1.79, below the 50-day MA of 1.79, and below the 200-day MA of 2.37, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 52.48 is Neutral, neither overbought nor oversold. The STOCH value of 62.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:9939.
Kintor Pharmaceutical Ltd Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | HK$5.07B | 8.47 | 47.76% | ― | 286.20% | ― | |
52 Neutral | HK$633.82M | -2.95 | -30.93% | ― | -17.22% | -6.13% | |
46 Neutral | HK$8.55B | -43.59 | -10.27% | ― | -31.77% | -177.01% | |
45 Neutral | HK$12.97B | -7.69 | -153.78% | ― | 70.26% | -12.79% | |
44 Neutral | HK$7.98B | -71.50 | -9.49% | ― | 68.12% | 81.84% | |
42 Neutral | HK$894.43M | -3.79 | -129.93% | ― | 647.17% | -8.86% |
* General Sector Average
HK:9939
Kintor Pharmaceutical Ltd
1.82
-0.59
-24.48%
HK:9966
Alphamab Oncology
8.77
-2.02
-18.72%
HK:1167
Jacobio Pharmaceuticals Group Co., Ltd.
6.44
-4.90
-43.21%
HK:1244
3D Medicines, Inc.
2.46
-5.50
-69.12%
HK:2171
CARsgen Therapeutics Holdings Ltd.
13.43
-9.63
-41.76%
HK:6855
Ascentage Pharma Group International
35.00
-46.25
-56.92%
Kintor Pharmaceutical Ltd Corporate Events
Kintor Pharmaceutical Boosts Revenue on Cosmetics Push but Stays in the Red
Aug 19, 2026
Kintor Pharmaceutical reported a sharp increase in revenue to RMB52.0 million for the six months ended June 30, 2026, up from RMB6.0 million a year earlier, driven mainly by global sales of its new high-end cosmetics brand KOSHINÉ that uses c...
Kintor Pharmaceutical Sets Board Meeting to Approve 2026 Interim Results
Aug 5, 2026
Kintor Pharmaceutical Limited has announced that its board of directors will convene on 19 August 2026 to review and approve the interim financial results for the six months ended 30 June 2026. The meeting will also authorize the publication of th...
Kintor Moves to Resolve Going-Concern Audit Issue With KX-826 Commercial Push
Jul 31, 2026
Kintor Pharmaceutical Limited has outlined measures to address a prior auditor’s disclaimer of opinion linked to concerns over its ability to continue as a going concern, focusing on improving operating cash flow, negotiating extended paymen...
Kintor Pharmaceutical Wins Strong Shareholder Backing at 2026 AGM
Jun 18, 2026
Kintor Pharmaceutical Limited reported that all resolutions proposed at its annual general meeting on 18 June 2026 were approved by shareholders via poll. The meeting covered adoption of the audited consolidated financial statements for the year e...
Kintor Advances KT-939 Cosmetic Raw Material With Strong Safety Data and China Registration Push
Jun 10, 2026
Kintor Pharmaceutical reported positive interim data from a long-term human safety trial of KT-939, a new cosmetic whitening raw material, showing no adverse skin reactions in 119 participants after 28 weeks of continuous topical use. The trial, w...
Kintor Showcases Promising KX-826 Hair Loss Data as It Pursues First-in-Class Status
May 31, 2026
Kintor Pharmaceutical has highlighted new clinical data for its in-house developed drug KX-826 at the 2026 World Congress for Hair Research in Seoul, underscoring its push into advanced hair loss therapies. The company reported that a phase III tr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.